All News
Dr. Alexis Ogdie on opioid use in PsA and axSpA, highlighting need for better interventions.
🔹21% of PsA pts (n=828) and 27% of axSpA (n=334) reported prescription opiate use.
🔹⬆️BASDI & HAQ-DI =>⬆️opiate use & costs
https://t.co/Id658ocDVf
#ACR21 Abst1777 @RheumNow
Pedro Castillo _Castillo_Pedro ( View Tweet)
Prof. Ami Shah: Patients with #scleroderma have an ⬆ risk of #cancer vs. general population
📌Data from 3 recent meta-analysis: Scleroderma pts have 1.4 to 1.8 fold increased risk of cancer
@RheumNow #ACR21 https://t.co/4uQN6y3tIn
sheila RHEUMarampa ( View Tweet)
Dr. Ami Shah shares her approach to cancer screening in patients with #scleroderma👇
@RheumNow #ACR21 https://t.co/chmlGe4iyl
sheila RHEUMarampa ( View Tweet)
TIF1-y: most dominant target in #cancer assoc'd #dermatomyositis
🔷Associated with cancer in every racial group tested; no assoc'n w/ juvenile DM
@RheumNow #ACR21 https://t.co/rPg1CQuNka
sheila RHEUMarampa ( View Tweet)
Factors Associated with Poor Vaccine Response in Rituximab: Dr. Yuzaiful Yusof (@Yuz6Yusof) discusses abstract #0437 presented at the #ACR21 annual meeting.
https://t.co/T0PFiZlbTa https://t.co/idj5T7j7ke
Links:
Dr. John Cush RheumNow ( View Tweet)
JAK Inhibitors in Refractory Adult and Childhood-Onset Still’s Disease
Dr. Bella Mehta ( @bella_mehta) shares abstract findings from #ACR21.
https://t.co/4FyXX5JIyZ https://t.co/YAJOwvLbLS
Links:
Dr. John Cush RheumNow ( View Tweet)
Update on Safety, Effectiveness of SARS-CoV-2 vaccines in SLE from Dr. Yuz Yusof ( @Yuz6Yusof)
It's almost a year since the Pfizer-BioNTech SARS-CoV-2 vaccine has been made available by the FDA under EUA. But is the vaccine safe for people with lupus?
https://t.co/i3HeCvS6El https://t.co/Tn0nWKrK4T
Links:
Dr. John Cush RheumNow ( View Tweet)
AxSpA/ PsA pts who completed ePRO Q between 2018-2021 showed 🔽 trend of PRO mostly in pts on biologic Rx
If ASDAS < 1.3 /PSAID-12 < 2➡️ pts were seen less frequently
⭐️🔽 clinic workload and better disease activity stratification
Abst # 1788 #ACR21 @RheumNow #ACRBest https://t.co/ilSrOjHQAk
swethaann23 swethaann23 ( View Tweet)
Abst 1515
Williams & colleagues studied role of CD4+ and CD8+ PD-1+ T cells in patients with early RA
- CD4+ and CD8+ T PD-1+ T cells were dominant cell types in synovial tissue
- 6 months after treatment, gene expression of CD4+ PD-1+ T cells decreased
#ACR21 @RheumNow https://t.co/TWLym8oHuK
Akhil Sood MD AkhilSoodMD ( View Tweet)
⭐️From 2012 – 2017 NIS data significant 🔽 in sepsis, SSTI, and UTI in patients with PsA despite the increased use of biologics over the years
⭐️No statistical difference pneumonia trend in PsA
Abst# 1783 #ACR21 @Rheumnow https://t.co/ToxgRb0acP
swethaann23 swethaann23 ( View Tweet)
We are live!
RheumNow Daily Recap - #ACR21 https://t.co/ILaj7CImXY via @YouTube
Links:
Dr. John Cush RheumNow ( View Tweet)
Rheumatologists and Healthcare Professionals: Join us tonight for RheumNow's #ACR21 Rheumatology Roundup at 7pm Eastern time - broadcast live on our YouTube Channel. Search RheumNow on YouTube.
https://t.co/dXNzeGFEds https://t.co/TJ7BEuLKsa
Links:
Dr. John Cush RheumNow ( View Tweet)
Direct-to-Patient (DA) PsA Screening Survey sent to patients with Ps without PsA led to earlier diagnosis of PsA in 0.4%(n=1149 patients) as compared to 0.3%(n=1150) receiving standard of care (SOC).
Mean times to PsA diagnosis
66d ▶️ DA
77d ▶️SOC
Abst# 1781 #ACR21 @RheumNow https://t.co/qxjPCU0vnI
swethaann23 swethaann23 ( View Tweet)
⭐️Prevalent drug utilization was not related to enthesitis activity
⭐️Prevalent use of cDMARDs 🔼physician GAS compared to TNFi/IL-17i
⭐️No correlation in disease activity scores amongst the use of different prevalent PsA drug Rx
Abst# 1782 #ACR21 @RheumNow @doctorRBC https://t.co/uzmTP1hZ2P
swethaann23 swethaann23 ( View Tweet)
What's Cool and Hot in Vasculitis: Dr. Janet Pope reviews abstracts #0505, #0466, #0430, #0507 and #0504, being presented at the #ACR21 annual meeting.
https://t.co/7XwjFuJEMM https://t.co/BC9wjPzNC0
Links:
Dr. John Cush RheumNow ( View Tweet)
RheumNow’s expanded coverage of the #ACR21 Annual meeting is sponsored in part by @Novartis. All content chosen by RheumNow & its faculty.
Dr. John Cush RheumNow ( View Tweet)
Dose Tapering of TNFi in AxSpA: Dr. Antoni Chan ( @synovialjoints) discusses abstract #0364 presented at the #ACR21 annual meeting.
https://t.co/pDnKFfeQdP https://t.co/7CZg2lkSFI
Links:
Dr. John Cush RheumNow ( View Tweet)
Abst 1517
Weinmann & colleagues studied prevalence of autoantibodies in Melanoma pts treated w/ ICI & developed rheumatic IRAE
- Most common rheumatic IRAE = inflammatory arthritis
- Higher prevalence of ANA in those tx w/ chemo prior to ICI
#ACR21 @RheumNow https://t.co/7qgogSMjUr
Akhil Sood MD AkhilSoodMD ( View Tweet)
Put those two RF together (essentially nailing down RA pts at risk of cancer):
age >65 or ever smoked, all tofa vs TNFi: HR 1.55 (1.05-2.30)
age >65 or ever smoked, tofa 5 bid vs TNFi: HR 1.44 (0.93-2.24)
neither RF, all tofa vs TNFi: HR 1.16 (0.53-2.55)
#ACR21 @RheumNow https://t.co/Uvr4wBhFVF
David Liew drdavidliew ( View Tweet)
So I guess you can look at this as you want:
Arguably, if you are <65 & a never smoker, then maybe the risk isn't there.
Once you start adding risk - maybe this is something we need to be having hard conversations with pts about.
Plenty to think about here...
#ACR21 @RheumNow
David Liew drdavidliew ( View Tweet)